Searched for
SYNGENE CEO
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- Biocon shares rise 1% after billionaire Kiran Mazumdar-Shaw names niece as successorBiocon's chairperson, Kiran Mazumdar-Shaw, has named her niece, Claire Mazumdar, as her successor, sparking a more than 1% jump in the comp...
- Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...
- Syngene's MD & CEO Jonathan Hunt steps down, Peter Bains named as new CEOJonathan Hunt has stepped down as the managing director and CEO of Syngene International, with Peter Bains appointed as the CEO Designate e...
- Syngene Q3 Results: Net profit rose 18% YoY to Rs 131 croreSyngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects single-digit r...
- Seeing good demand for biologics manufacturing: Syngene CEO Jonathan HuntIn an interview to ET, Jonathan Hunt, CEO and MD of Syngene said the company has spare capacity and is also investing on expansion of micro...
- Syngene International Q1 results: Net profit rises 33% to Rs 77 cr; John Shaw to step down from boardConsolidated revenue from operations of the company stood at Rs 594.5 crore for the quarter under consideration. It was Rs 421.6 crore for ...
- Syngene International Q3 results: Profit rises 11% to Rs 102 crRevenue from the operations stood at Rs 585 crore in the quarter under review. It was Rs 519 crore in December quarter 2019-20, it added.
- Syngene International Q4 results: Profit up 20% to Rs 120 croreThe company had posted a net profit of Rs 100 crore for the corresponding period of the previous fiscal.
- Syngene International Q2 profit up 64% at Rs 128 croreTotal income stood at Rs 485.2 crore for the quarter under review as against Rs 436.8 crore for the same period a year ago, it added.
- Syngene lines up $200 million capex to boost manufacturingSyngene offers integrated drug discovery and development services with capabilities in medicinal chemistry, biology and toxicology.
- Syngene Q1 Net up 28% at Rs 60 croreThe company had posted a net profit of Rs 46.6 crore for the corresponding period of the previous fiscal, Syngene International said in a f...
- Syngene International Q3 net profit up 31% at Rs 59 croreSyngene International has reported a 31.25 per cent rise in its net profit to Rs 58.8 crore for the third quarter ended December 31.
- Syngene Q3 net up 31% to Rs 59 croreBiocon's contract research arm Syngene International reported 31.25% rise in net profit to Rs 58.8 crore for the third quarter of 2015-16 f...
- Syngene appoints Jonathan Hunt as CEO-designateHunt will take charge after the retirement of current CEO Peter Bains in March, Syngene International said in a regulatory filing.
- Syngene gets FIPB nod to raise foreign investment to 44%Syngene, a subsidiary of Biocon, said it has received the Foreign Investment Promotion Board approval to raise foreign investment to 44 per...
- Biocon arm Syngene appoints Peter Bains as CEOBains has been a director of Syngene, since 2011. Syngene had yesterday said it would set up a new plant at Mangalore SEZ to manufacture ph...
- Biocon Q3 Net dips 13% to Rs 91 crore; to offload 10-15% in SyngeneBio-pharmaceuticals contributed Rs 541 crore and research services Rs 220 crore to revenue for the reporting quarter.
Load More
